Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5626_Библиотеки_им_академика_М_И_Перельмана.pdf
21.3 Clinical Pharmacognosy 431
can be standardized using mass spectrometry [67]. Mass
spectrometry is not a true quantitative approach and can
only show the presence of specific peptides originating
from allergens within an extract; it cannot reveal information on the molecules’ immunogenic or allergic qualities.
Consequently, no technique exists that can simultaneously
analyze all significant characteristics (physicochemical,
related to structure, and immunological attributes) of the
different parts that make up complicated mixtures like
allergen extracts [68].
Table 21.2 Quality control techniques with advantages and disadvantages for allergen extract.
Sr. No Techniques Advantages Disadvantages
1 Measurement of protein
concentrations
(quantitative by nitrogen
determination and
qualitative by
SDS-PAGE)
2 Measurement of
allergenic activity and
IgE reactivity (Basophil
activation, Skin testing,
and IgE reactivity)
3 Mass spectrometry Recognizes items originating from
4 Circular dichroism and
size exclusion
5 Enzyme-linked
immunosorbent assay for
allergen quantification
6 Qualitative allergen
detection (e.g.
immunoblotting)
7 Immunization Details how allergen extracts, even
Quantifies protein quantity and
quality; suitable for denatured
allergen extracts.
Evaluate an extract’s allergenic
potential and IgE reactivity.
allergens based on their distinctive
mass.
Discover how proteins fold and how
they aggregate.
Enables specific allergens
measurement.
Uses particular antibody probes to
represent the allergens present in an
extract visually.
denatured extracts, can produce
allergen-specific IgG and IgE
antibodies in animals when they are
immunized; this information also
applies to allergen extracts that are
denatured.
21.3.3.2 Methods for the Quality Control of Allergenic Extracts with their Advantages and Disadvantages
Many techniques for ensuring the quality control of allergen extracts and their benefits and drawbacks are listed in
Table 21.2.
An illustration of quality assurance, one of the first techniques for allergen extract quality control was introducing
a method for calculating the total protein levels. While
measuring protein content, it does not specifically identify
Fails to distinguish between allergic and
nonallergenic components in extracts, fails to identify
allergen molecules, and fails to provide information
on immunogenicity.
It does not distinguish between different allergens,
only displays IgE and allergenic reactivity for one
standard, and only uses a limited quantity of the
standard available; outcomes may differ based on
the standard and may not accurately reflect the
circumstances of any given patient at any given
time; does not provide information regarding
immunogenicity; and does not apply to allergen
extracts that are denatured.
Unsuitable for precise quantification, inability to
distinguish between allergens that are fully
immunogenic and non-allergic allergen-derived
materials, such as peptides, and allergen fragments,
and lack of information on immunogenicity.
Generally, it is only appropriate for pure proteins;
it does not disclose information regarding
immunogenicity, IgE reactivity, or allergenic activity;
it does not offer quantitative data; and it does not
apply to allergen extracts that have been denatured.
Not available for every allergen, impossible to
distinguish between allergen-derived materials and
allergen isoforms, unable to quantify allergenic
activity and IgE reactivity consistently, unable to
supply data regarding immunogenicity, and
inapplicable to allergen extracts that are denatured.
It does not permit the measurement of allergens,
cannot recognize nonallergenic substances or
materials, and does not provide information
regarding immunogenicity or allergic activity.
It does not permit the assessment of specific
allergens, does not identify allergens, and does not
provide information regarding the allergenic activity
and IgE reactivity of the extract; results obtained for
specific animals may not accurately reflect human
immunization and can cause cross-reactive
antibodies that react with other allergen sources
as well.
432 21 Clinical Pharmacognosy
allergies or their characteristics. Later, as added approaches
for quality control, techniques for determining IgE sensitivity and the allergenic activity of allergen extracts were
devised. These techniques rely on patient-derived reagents
because these extracts are tested for reactivity using basophil activation, IgE antibodies, or skin testing. Because
each allergy patient reacts differently to allergens and has a
distinct sensitivity to them, the findings of potency testing
based on patient materials will vary greatly [69]. Except for
determining the degree of allergic activity reduction concerning an unmodified allergen extract, potency assays
evaluating allergenic activities cannot be applied to extracts
of allergen that have undergone modifications to decrease
allergen activity.A number of biophysical and biochemical
techniques have also been created. These comprise, for
instance, size exclusion that enables the identification of
allergen peptides, mass spectrometry, circular dichroism,
and the examination of protein fold and aggregation behavior, respectively [70]. Specifically, it has been proposed that
mass spectrometry is a potent technique for standardizing
allergen extracts. While gel filtration and circular dichroism are excellent tools for analyzing individual pure molecules, they are inappropriate for handling complicated
allergen combinations. The qualitative examination of
allergen extracts is made possible by immunoblotting and
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, which can distinguish between aggregation, intact
allergens, and breakdown products based on molecular
mass. Determining the quantities of entire allergens is possible by using allergen-specific antibody probes in quantitative enzyme-linked immunosorbent assays. Animals can
be immunized with the developed vaccine to determine
whether an allergen extract can cause the formation of
allergen-specific IgG antibodies that prevent patients’ IgE
binding [71]. It is advised to conduct immunization investigations on outbred animals like rabbits because antibodies produced by allergy vaccines in inbred mouse strains
recognize different epitopes than those made in allergic
people. It is thus possible to assess if the IgG antibodies
produced in the animals can prevent the IgE binding to
allergens and the initiation of effector cells in allergic
humans. Indeed, a recent study demonstrating that recombinant allergen-specific antibodies can be used to immunize against cats with allergies passively highlights the
significance of blocking antibodies for treatment success
and the necessity of testing allergy vaccines for the induction of blocking antibodies in model systems [72].
21.3.3.3 Allergenic Extracts for Diagnosis and Treatment (Table 21.3)
Table 21.3 is a compilation of allergen extracts that we discovered to be recorded or accessible across several continents and nations, together with the relevant web pages of
the regulatory bodies that provide the information when
applicable [73–75]. We have examined a few nations as
examples, including Taiwan and Japan in Asia, the USA,
Germany, and Russia. Yet it is already abundantly evident
from this small sample of nations how diverse the laws are
throughout the world. Allergens, whether used as in vivo test
allergens or for therapy, appear to have one thing in common: they are regarded as biological medicinal goods and, as
such, need marketing authorizations, which are often
granted for the final product. Injectable allergen extracts,
standardized and nonstandardized, are sold in the USA by
numerous producers. Nevertheless, we could not locate published cutting-edge clinical trials that confirm most of these
products’ safety, specificity, and effectiveness. Some extracts
accessible as tablets for sublingual treatment have been the
subject of double-blind, placebo-controlled, randomized
clinical studies that adhere to the regulations established for
pharmaceutical products. For Germany, the situation was
comparable. The Paul Ehrlich Institute, which oversees the
record of pharmaceuticals in Germany, lists extracts for skin
testing and provocation testing from several companies on
its homepage. However, we could not locate clinical study
documentation for these test allergen extracts. Similar circumstances were discovered in Japan, Taiwan, and Russia,
where there are only a few allergen extracts on hand.
Producing allergen extracts accessible without adhering to
new regulations for allergy products is one option; these
products are known as named patient products, and doctors
can prescribe them for specific patients. It’s crucial to
remember that these items do not adhere to the present
medicinal product regulations because the evidence supporting them is very less (i.e. expert suggestion), and they are
prescribed to specific patients. In the United States, allergy
products are governed by two separate sets of laws: the
Federal Food, Drug, and Cosmetics Act regulates them as
drug goods, and the Public Health Service Act regulates
them as biological medicinal products. Both laws need a
marketing authorization known as a biologics license application (BLA). The BLA must prove the product’s safe, pure,
and efficient manufacturing under GMP. Thus, by the current GCP legislation, marketing permission is contingent
upon completing placebo-controlled investigations, doubleblind, randomized. Clinical studies are being conducted due
to the pharmaceutical industry’s request to the European
Union (EU) to submit the required documentation for their
goods. Thus, it is not shocking that there’s a significant
chance that a large number of naturally occurring allergen
extracts – particularly those used in in vivo testing – will vanish from the EU. While other countries may have different
regulatory environments, it is not implausible that there will
be a sudden increase in the demand for quality control
regarding allergen extracts due to the ongoing rise in healthcare costs, which will require comprehensive clinical studies
21.4 Clinical Studies on Botanicals and Dietary Supplements 433
Table 21.3 Diagnostic and therapeutic allergen extracts registered in the USA, Germany, Russia, and Asia.
Sr. No Country Registered diagnostic and therapeutic allergens
1 USA Injectable allergen extracts are standardized
Cat Hair (Felis domesticus): seven manufacturers
Cat Pelt (Felis domesticus): two manufacturers
Mite D.f. (Dermatophagoides farinae): six manufacturers
Kentucky (June) Bluegrass (Poa pratensis): six manufacturers
Bermuda Grass (Cynodon dactylon): six manufacturers
Sweet Vernal Grass (Anthoxanthum odoratum): six manufacturers
2 Germany Extracts of allergens for skin prick test:
Weed pollen, grass, and corn
Latex
Tree pollen
Venoms
Food
Yeasts and molds
Animal dander/hair
Storage mites/house dust mites
3 Russia For in vivo diagnostic reasons:
Water-salt allergen extracts manufactured by AO “Biomed” Mechnikov
Water-salt allergen extracts manufactured by NPO Microgen
4 Asia
Japan For in vivo diagnostic reasons:
Extracts from Tori Pharmaceutical Co.
Allergen Scratch Extract Positive control “TORII” Histamine
Dihydrochloride
10 000 AU mL
Allergen extracts for Scratch test: HDM “TORII” 100 000 JAU mL1,
Dermatophagoides pteronyssinus extract 10 000 AU mL
Taiwan Allergen extracts available from Allermed (USA), now combined by Greer Co.
China Allergen extracts available from:
Stallergenes Greer. Co. (USA), ALK (Horsholm, DenmarK),
WolwoPharma. Co. (China)
1
extract of Dermatophagoides farinae,
1
.
to validate the security and effectivity of medications.
Therefore, to provide dependable, safe, effective, and affordable choices for therapy and in vivo diagnosis and eventually
to differentiate between therapeutic and diagnostic allergen
preparations, it will be imperative to step up the conversations between major allergy societies and international control agencies [76].
21.4 Clinical Studies on Botanicals
Traditional remedies and botanical dietary supplements
are frequently the original sources of healthcare for illness
prevention and treatment in impoverished nations. These
products are mainly used for maintaining health, especially in the United States, where 20% of adults claim to use
botanical dietary supplements, and to a lesser level in
Europe. The global market for botanical nutritional treatments was estimated to be worth $33 billion in 2010. The
use of dietary therapies has gradually raised in the US
since the United States Dietary Supplement and Health
Education Act of 1994 excluded these items from classification as medications or foods. In 2013, the United States
spent over US$ 6 billion on dietary supplements [77]. Over
the previous 20 years, there has been a steady rise in the
utilization of botanical nutritional supplements worldwide. While regulations vary widely, most markets require
minimum botanical verification and quality assurance.
The U.S. Food and Drug Administration (FDA) does not
434 21 Clinical Pharmacognosy
demand premarketing approval or proof of the effectiveness of herbal dietary supplements; they are claimed to
have drug-like properties. Moreover, the producer is still in
charge of ensuring the security of herbal dietary supplements, and post-marketing monitoring for adverse reactions is the only way to do so. Botanical dietary supplements
are regulated as food supplements or as medications in
Europe [78]. Unless botanical, nutritional supplements are
combinations of botanicals with a long tradition of human
use, in which case they are referred to as “traditional herbal
medicinal products” (HMP) and are only subject to quality
and safety regulations, as in the United States, the EU mandates substantiated evidence of safety and efficacy for
botanical dietary supplements if therapeutic claims are
made. However, the EU classifies botanical nutritional
supplements as food supplements when they are sold for
health promotion or maintenance. If any health claims are
made, proof of efficacy must be supplied. Customers who
purchase botanical dietary supplements anticipate a reliable and secure product, and significant markets’ GMP regulations and labeling standards contribute to attaining
these goals. However, few carefully planned clinical trials
have demonstrated efficacy, and safety concerns, including
potential drug-botanical reactions, remain ignored for
many botanicals. The UIC Botanical Centre for Dietary
Supplements Research was founded in 1999 and has since
advanced a set of best practices for the repeatable manufacturing and assessment of the efficacy and safety of botanical dietary supplements [79].
21.4.1 Phase I, II, III, and IV Trial on Botanicals, and Dietary Supplements with Example
In the end, human testing is necessary to ascertain the
safety and effectiveness of botanical dietary supplements.
Similar to medication trials, clinical studies of botanical
nutritional supplements may be conducted in escalating
phases, with more human volunteers in each step. Shortterm Phase I clinical trials expose small groups of participants (often less than 20 per group) to increasing amounts
of the botanical supplement to find a safe range of dosages
and to detect any adverse impacts. Phase II trials assess both
safety and efficacy that last longer and involve more significant numbers of human subjects – usually in the hundreds.
Phase III clinical trials are designed to monitor adverse
effects and prove efficacy with substantially bigger subject
groups. Lastly, phase IV studies are predicated on post-marketing safety and efficacy surveillance involving various
human groups and, if relevant, prolonged product usage.
Phase I trials encompass several types, such as pharmacokinetics studies, maximum tolerated dosage determination, and drug-botanical interaction investigations.
Studies on the maximum dosage and pharmacokinetics are
frequently conducted in combination to evaluate the influence of dosage on pharmacokinetics. In pharmacokinetics
investigations, serum concentrations of active compounds,
metabolites of natural products, or marker natural products are assessed (typically by LC-MS/MS) when multiple
blood samples are taken many hours after a single intake of
the botanical dietary supplement. The area under the concentration–time curve (AUC), apparent clearance (CL/F),
terminal elimination constant, apparent volume of distribution (Vd/F), maximum serum level (Cmax), time for
attaining peak level (Tmax), and elimination half-life
(T1/2) are then computed as pharmacokinetics parameters. These figures aid in establishing the intervals and
proper dosages between doses, both necessary to ensure
protection and effectiveness. In a phase I dose escalation
and pharmacokinetic study, the UIC Botanical Centre for
Dietary Supplements Research studied an ethanolic extract
of spent hops (Humulus lupulus hop cones that had been
previously stripped of bitter acids and essential oils using
supercritical fluid carbon dioxide) in a group of five postmenopausal women. This work demonstrates how several
active ingredients in a botanical extract can be given and
evaluated concurrently in a phase I clinical study. In this
instance, each serum sample’s four constituents were
measured using UHPLC-MS/MS [80].
Phase II clinical studies assessing efficacy and safety
necessitate suitable clinical design in addition to using
botanically GMP-produced botanical dietary supplements,
standardized, and authenticated. A phase II trial should
have the following optimal experimental design: subjects
should be randomly assigned to different study arms;
double-blinding should be used to prevent subjects and
researchers from knowing which treatment group a subject
is in until the investigation is finished; a crossover or
placebo-control design should be used in which subjects
act as their controls; and the number of subjects should be
sufficient to guarantee statistically significant results.
Including a positive control arm in some research may also
be beneficial. Double-blinding the treatment groups contributes to preventing bias from the study’s investigator
and participants during the trial. Randomization helps prevent bias in assigning recently enrolled patients to one arm
of the research or another. Controls ensure that phase II
trial results are attributable to the dietary supplements
made of botanicals and not to chance or unanticipated outside influences. Lastly, insufficient power – a lack of subjects – is the most prevalent problem with phase II clinical
studies of botanical dietary supplements. This means that
the results are not statistically significant.
The UIC Botanical Centre for Dietary Supplements
Research conducted a phase II clinical study incorporating
all the previously discussed design components. The trial
focused on the safety and effectiveness of red clover
21.5 Clinical Pharmacokinetics 435
(Trifolium pratense L.) and black cohosh in treating menopausal vasomotor symptoms. The menopausal women
were recruited in the 12-month intervention. The experiment included two arms of botanical dietary supplements,
a placebo arm, and a positive control arm that represented
traditional hormone therapy (Prempro). After a year,
women in all study arms – including the placebo group,
which reported a 60% reduction in hot flashes and night
sweats – exhibited fewer vasomotor symptoms. If the study
had not included a placebo arm, it could have implied that
the red clover and black cohosh interventions improved
vasomotor signs, even though the results were the same as
those of a placebo. Women using either botanical dietary
supplements experienced no adverse effects, which is significant since there had been some worry about red clover’s potential to create blood clots or black cohosh’s
potential to cause liver damage. The addition of a positive
control helped this unsuccessful trial since it demonstrated
that the study’s design might produce a favorable result
with the traditional hormone replacement arm [81].
Clinical trials must be completed in all stages for pharmaceuticals and botanical dietary supplements classified as
medications; however, for most commercialized botanical
nutritional supplements, only phase IV safety assessment is
usually conducted. Regulatory agencies have occasionally
prohibited all botanical dietary supplements incorporating
specific botanical species or recalled particular products
due to safety issues that surfaced during phase IV monitoring. For instance, in 2004, the United States FDA prohibited
all dietary supplements that contained ephedra (Ephedra
sinica) due to the high risk of seizures, myocardial infarctions, cerebrovascular accidents, and severe mental disorders, as well as the deaths of young adults.
It is unclear whether all available botanical dietary supplements on the market will be evaluated through each
stage of clinical studies or evaluated using the step-by-step
procedure described in this review. Manufacturers of
botanical dietary supplements are bound to require clinical
evidence of safety and efficacy to make therapeutic claims.
Moreover, regulatory bodies may demand the completion
of preclinical investigations like those described in this
review. Botanical dietary supplements with clinical safety
testing or, better yet, with testing for both safety and efficacy are likely to have a marketing edge over unproven
goods, even if they are not mandated [82].
21.5 Clinical Pharmacokinetics
Simultaneous usage of a medicinal plant can influence the
therapeutic effectiveness of a medicine or its unforeseen,
undesired adverse events. Particularly, components in the
extracts of medicinal plants may affect the drug’s half-life,
metabolism, and bioavailability, which could result in toxicity or an inability to generate the desired therapeutic
impact. Here, we attempt to concentrate on clinical
research that advances our understanding of how some
herbal remedies may affect the pharmacokinetics of concurrently delivered medications. Additionally, in vitro
research helps predict possible interactions of drugs with
herbal medicines. Specifically, they aid in clarifying the target of the cell and the mode of action (induction or inhibition) of a single herbal medicine ingredient. The challenge
of comparing outcomes from human trials utilizing various plant extract types is also examined. The European
Medicinal Agency’s (EMA) “Herbal Medicines for Human
Use” section lists the herbal medicines under discussion as
some of the most significant sales [83].
21.5.1 Clinical Support of the Herbal-drug Interaction Caused by the Blockage of Transporters and Drug-metabolizing Enzymes
21.5.1.1 Hydrastis Canadensis
Numerous investigations have demonstrated the ability of
goldenseal extracts to suppress CYP enzyme activity, supporting the theory that these extracts, at least in vitro, inhibit
several CYP isoforms involved in drug disposal, including
2D6, 3A4, 2C8, and 2E1. With IC50 values of 0.66, 0.98, and
0.18%, respectively, extracts of goldenseal inhibited the
CYP2D6-mediated bufuralol 10-hydroxylation, CYP2C9mediated diclofenac 4’-hydroxylation, and CYP3A4mediated testosterone 6ß-hydroxylation activities in human
hepatic microsomes. These extracts contained approximately comparable concentrations of the two hydrastines,
methylenedioxyphenyl alkaloids and berberine. Specifically,
hydrastine or goldenseal both exhibit non-competitive suppression of testosterone 6ß-hydroxylation activity, and
hydrastine’s methylenedioxyphenyl moiety likely interacts
with the enzyme’s heme iron to produce a stable heme
adduct, which causes CYP3A4 to become inactive [84]. In
turn, it was shown that goldenseal extracts inhibited the
activity of CYP2E1 and CYP2C8 in human liver microsomes. Goldenseal inhibits CYP2E1 strongly, and the alkaloids berberine, hydrastine, and canadine appear to be
involved. With Ki values ranging from 18 for berberine
to 2.8 for hydrastine, these drugs inhibited CYP2E1.
Furthermore, goldenseal methanolic and aqueous extracts
1
had IC50 values of 6.3 and 6.7 g mL
, respectively, inhibiting CYP2D6 activity in human liver microsomes. Due to
goldenseal’s ability to suppress CYP3A4 in vitro, several
research studies have examined how goldenseal administration affects how CYP3A4 substrate medications behave
in humans [85].
The first evidence that goldenseal prevents drug metabo-
lism in vivo comes from an investigation that examined the
436 21 Clinical Pharmacognosy
effects of long-term goldenseal supplementation (900 mg,
three times daily for 28 days) on CYP2E1, CYP2D6,
CYP1A2, and CYP3A4/5 activity in healthy volunteers
using single-time point phenotypic metabolic ratios. Using
debrisoquin urinary recovery ratios (8-h collection), paraxanthine/caffeine serum ratios (6-h sample), 6-hydroxy
chlorzoxazone/chlorzoxazone serum ratios (2-h sample),
and hydroxy midazolam/midazolam serum ratios (1-h
sample), pre-and post-supplementation phenotypic trait
measurements were measured for CYP2D6, CYP3A4/5,
CYP2E1, and CYP1A2. Comparing the means of the preand post-supplementation phenotypic ratios revealed that
goldenseal significantly (approximately 40%) inhibits the
activity of CYP3A4/5 and CYP2D6 but not CYP2E1 or
CYP1A2. These preliminary findings were corroborated by
a follow-up study conducted by the same authors, which
assessed the impact of goldenseal on the pharmacokinetics
of midazolam (a CYP3A-sensitive probe) using traditional
concentration-time profiles and AUC values. It was found
that taking a 14-day supplement of goldenseal (1.323 mg,
three times a day) significantly raised the Cmax (by 41%),
AUC (0-∞) (by 62%), and t1 ⁄2 (by 57%) of oral midazolam
administration, while also significantly reducing apparent
oral clearance (by 36%). These findings suggest that goldenseal may enhance the oral bioavailability and decrease
the entire hepatic clearance of CYP3A substrate medications, posing a severe risk of toxicity and adverse drug reactions in patients taking CYP3A4 substrate medications
with limited therapeutic indices [86, 87].
21.5.1.2 Kava Kava
It has been demonstrated that Kava Kava (Piper methysticum) extract inhibits several CYPs in vitro, including 3A4,
2C9, 2C19, 1A2, and 2D6, but not 2E1, 2A6, or 2C8.
However, Zou and associates (2004) also demonstrated
CYP2E1 inhibition. However, according to single-time
point phenotypic metabolic ratios, kava extract therapy for
1
28 days (at 138 mg day
kava lactones) or 14 days (at
253.5 mg day1 kava lactones) did not affect CYP2D6,
CYP1A2, or CYP3A4/5 activity in healthy volunteers.
1
Similarly, kava supplementation (253.5 mg day
kava lactones for 14 days) did not result in any noteworthy changes
to the pharmacokinetics of the CYP3A4 substrate medication midazolam. After 28 days of therapy with kava extract
1
at a dose of 138 mg day
, kava lactones caused a statistically significant (about 40%) decrease in CYP2E1 activity,
which supported Zou et al. in vitro findings but contradicted Mathews et al. Lastly, the in vivo details that are now
available indicate that additional research is required to
determine whether kava can decrease human drug metabolism. Meanwhile, patients should be monitored appropriately when co-administering kava with medications that
are undergoing CYP-mediated metabolism to avoid potentially inhibiting their biotransformation and increasing
their risk of unwanted reactions or drug toxicity [88, 89].
21.6 Phytoequivalence
To demonstrate that one herbal extract is equal to another,
more precisely, to one that has undergone clinical validation, the idea of phytoequivalence was established in
Germany in the middle of the 1990s. An extract’s composition affects its pharmacological and physiological activity;
nevertheless, because extracts contain many ingredients,
accurate techniques are required when comparing them.
Specific guidelines for herbal extracts or botanicals are still
lacking, even though equivalency among pure compounds
or isolated molecules is attainable utilizing current chromatographic and spectroscopic techniques. This is mainly
caused by the herbal extracts’ multi-component structure
and the inherent diversity of their ingredients. However,
phytoequivalence can be accurately addressed using mathematical and chemometric techniques [90].
There are currently a few studies discussing the bioequivalence of a phytomedicine about another product
that might be the focus of future investigation, and there
are no specific guidelines regarding the bioequivalence of
HMP. Nevertheless, there are helpful indicators to compare
extracts, specifically:
1. Posology and tress,
2. Administration route,
3. Species of plants,
4. Origin of plant parts,
5. Extraction solvent(s),
6. Drug-to-extract ratio, and
7. Physical state.
A few documents have addressed comparing HMPs.
Herbal extracts are a complicated combination of several
chemical classes, and the term “phytoequivalence” refers
to the correlation between each active ingredient’s natural
variability.This notion was established in Germany to
ensure consistency in herbal goods and compare extracts.
A precise chemical profile, such as chromatographic fingerprinting, must be created by taking into account as
many ingredients as feasible and contrasted to the profile
of a reference product that has been clinically established.
We have reviewed the best approaches to dealing with this
problem by combining facts from the literature with our
own experience [91]
A chromatographic and spectroscopic fingerprinting can
accurately depict a phytochemical profile, which is crucial
for assessing the consistency of an extract’s manufacture.
References 437
The authorities advise against this because of the inherent
complexity of herbal medications. As a result, identification tests listed in a pharmacopeia monograph cannot capture an extract’s total diversity. Throughout the stability
research, the chromatographic profiles that back up the
fingerprint should stay similar from the beginning (time 0)
to a certain point in storage. However, the word “comparable” must be defined because it is ambiguous. The idea of
phytoequivalence was created to guarantee and preserve
the effectiveness of herbal products.
Herbals, unlike chemically defined treatments, can
never be identical due to the range of essential ingredients.
Because the necessary components in the initial plant
material naturally vary, no two sets of herbal products from
the same producer can ever be the same. This is why essential similarity or equivalency should be used instead of
identity when comparing herbal items.
Pharmacopeia standards serve as the foundation for the
initial evaluation. Still, since each component of an extract
may impact its activity, more appropriate and focused techniques should be considered for the extract’s overall assessment. These techniques include the following:
1. The choice of the reference sample.
2. The selection of the analytical techniques (e.g. LC-MS,
GC-MS, NMR, HPLC, GC, FT-IR, etc.).
3. The statistical analysis (e.g. noise and drift removal,
mean centering, binding, and alignment) utilized for
the comparison) [92].
21.7 Future Prospects of Clinical Pharmacognosy
Clinical pharmacognosist education will be necessary in
the future to provide additional information on many clinical application elements of natural health goods. Developing and disseminating clinical pharmacognosy features
may improve everyone’s health by enabling the sensible
use of traditional and herbal medications and adding
standard clinical values to them. A clinical pharmacognosist is qualified to give accurate and comprehensive advice
regarding dietary supplements, natural health products,
and all pharmacological and medicinal aspects of plants.
This field may play essential and fascinating functions in
locating, evaluating, standardizing, managing, recording,
and identifying these evidence-based natural health products. The results of successful natural remedies are
increased, mainly when a systematic assessment of randomized controlled trials evaluating herbal medicines for
various ailments is conducted. For example, a recent systematic review of traditional Iranian medicine (TIM) has
led to new discoveries and avenues for research in inflammatory bowel disease. It’s interesting to note that several
disease names or even terminology for herbal substances
differ from those in modern usage in TIM; therefore, scholars must be highly cautious when studying TIM and translating it into modern English. Increasing our focus on these
potent herbs will help us find and produce new natural
medications.
21.8 Conclusion
Clinical pharmacognosy holds the potential to offer favorable effects in managing various diseases. However, it is crucial to recognize that herbal-drug interactions can manifest
as either beneficial or adverse effects. Therefore, meticulous monitoring of these interactions is imperative.
Additionally, the concept of phytoequivalence becomes
pivotal in surveilling herbal extracts. Addressing these
challenges with precision can enable clinical pharmacognosy to significantly contribute to the healthcare system,
promoting positive health outcomes.
References
1 Stubbings, J., Nutescu, E., Durley, S.F. et al. (2011).
Payment for clinical pharmacy services revisited.
Pharmacotherapy: The Journal of Human Pharmacology
and Drug Therapy 31 (1): 1–8. https://doi.org/10.1592/
PHCO.31.1.1.
2 Kazemi, M., Eshraghi, A., Yegdaneh, A. et al. (2012).
“Clinical pharmacognosy”-A new interesting era of
pharmacy in the third millennium. DARU Journal of
Pharmaceutical Sciences 20: 1–3. https://doi.org/
10.1186/2008-2231-20-18.
3 Blondeau, S., Do, Q.T., Scior, T. et al. (2010). Reverse
pharmacognosy: Another way to harness the generosity
of nature. Current Pharmaceutical Design 16 (15):
1682–96. https://doi.org/10.2174/138161210791164036.
4 Inić, S. and Kujundžić, N. (2011). The first independent
pharmacognosy institute in the world and its founder
Julije Domac (1853–1928). Die Pharmazie-An
International Journal of Pharmaceutical Sciences 66 (9):
720–6. https://doi.org/10.1691/PH.2011.1025.
5 Shinde, V., Dhalwal, K., and Mahadik, K. (2008). Some
issues related to pharmacognosy. Pharmacognosy
Reviews 2 (3): 1.
6 Upton R, Graff A, Jolliffe G, editors. et al.
American herbal pharmacopoeia: botanical
pharmacognosy-microscopic characterization of
botanical medicines. CRC Press; 2016 Apr 19: 3–30.
438 21 Clinical Pharmacognosy
https://doi.org/10.1201/B10413/AMERICAN-HERBALPHARMACOPOEIA-GEORGINA-JOLLIFFEREINHARD-L.
7 Tyler, V.E., Brady, L.R., and Robbers, J.E. (1988).
Pharmacognosy. 9th edit. Lea and Fabiger, Philadelphia.
Poultry Science 50 (6): 804–7.
8 Greenish, H.G. (1909). A text book of materia medica,
being an account of the more important crude drugs of
vegetable and animal origin, designed for students of
pharmacy and medicine. London: J. & A. Churchill:
1–20. https://openlibrary.org/books/OL27001335M/
A_text_book_of_materia_medica.
9 Delgoda, R. (2016). Pharmacognosy: Fundamentals,
applications and strategies. Massachusetts: Academic
Press; 2016 Nov 11: 3–30.Retrieved January 29, 2024,
from https://www.google.co.in/books/edition/Pharmac
ognosy/qEl8DAAAQBAJ?hl=en.
10 Kraemer H. Scientific and Applied Pharmacognosy
Intended for the Use of Students in Pharmacy: As a Hand
Book for Pharmacists, and as a Reference Book for Food
and Drug Analysts and Pharmacologists. Wiley; 1920:
xiii–xxviii. Retrieved January 29, 2024, from https://
openlibrary.org/books/OL33091517M/Scientific_and_a
pplied_pharmacognosy.
11 Selvam, A.B. (2010). Is the term substitution relevant to
pharmacognosy and/or vegetable crude drug industry?
Pharmacognosy Research 2 (5): 323. https://doi.org/10.
4103/0974-8490.72333.
12 Silverman, B.W. (2011). Research and development in
forensic science: a review. London: Home Office: 1–24.
https://www.gov.uk/government/publications/researchand-development-in-forensic-science-review.
13 Huang, L., Xiao, P., Guo, L. et al. Molecular
pharmacognosy. Science China Life Sciences 53: 643–52.
https://doi.org/10.1007/S11427-010-4006-4/METRICS.
14 Zeid, I.M. (2009). Effect of arginine and urea on
polyamines content and growth of bean under salinity
stress. Acta Physiologiae Plantarum 31: 65–70. https://
doi.org/10.1007/S11738-008-0201-3.
15 Young, A., Chaudhry, H.J., Pei, X. et al. (2015). A census
of actively licensed physicians in the United States, 2014.
Journal of Medical Regulation 101 (2): 7–22. https://
doi.org/10.30770/2572-1852-101.2.7.
16 Cordell, G.A. and Colvard, M.D. Natural products and
traditional medicine: Turning on a paradigm. Journal of
Natural Products 75 (3): 514–25. https://doi.org/10.1021/
NP200803M/ASSET/IMAGES/MEDIUM/NP-201100803M_0001.GIF.
17 Couteur, D.G., Ford, G.A., and McLachlan, A.J. (2010).
Evidence, ethics and medication management in older
people. Journal of Pharmacy Practice and Research 40
(2): 148–52. https://doi.org/10.1002/J.2055-2335.2010.
TB00523.X.
18 Hasani-Ranjbar, S., Nayebi, N., Larijani, B. et al. (2009).
A systematic review of the efficacy and safety of herbal
medicines used in the treatment of obesity. World
Journal of Gastroenterology: WJG 15 (25): 3073. https://
doi.org/10.3748/WJG.15.3073.
19 Rahimi, R., Mozaffari, S., and Abdollahi, M. (2009).
On the use of herbal medicines in management of
inflammatory bowel diseases: a systematic review of
animal and human studies. Digestive Diseases and
Sciences 54: 471–80. https://doi.org/10.1007/S10620008-0368-X.
20 Hasani-Ranjbar, S., Larijani, B. and Abdollahi, M.
(2009). A systematic review of the potential herbal
sources of future drugs effective in oxidant-related
diseases. Inflammation & Allergy-Drug Targets
(Formerly Current Drug Targets-Inflammation &
Allergy)(Discontinued) 8 (1): 2–10. https://doi.org/10.21
74/187152809787582561.
21 Hasani-Ranjbar, S., Nayebi, N., Larijani, B. et al. (2009).
A systematic review of the efficacy and safety of herbal
medicines used in the treatment of obesity. World
Journal of Gastroenterology: WJG 15 (25): 3073. https://
doi.org/10.3748/wjg.15.3073.
22 Hasani-Ranjbar, S., Nayebi, N., Moradi, L. et al. (2010).
The efficacy and safety of herbal medicines used in the
treatment of hyperlipidemia; a systematic review.
Current Pharmaceutical Design 16 (26): 2935–47.
https://doi.org/10.2174/138161210793176464.
23 Efferth, T. and Kaina, B. (2011). Toxicities by herbal
medicines with emphasis to traditional Chinese
medicine. Current Drug Metabolism 12 (10): 989–96.
https://doi.org/10.2174/138920011798062328.
24 Ulbricht, C., Chao, W., Costa, D. et al. (2008). Clinical
evidence of herb-drug interactions: a systematic review
by the natural standard research collaboration. Current
Drug Metabolism 9 (10): 1063–120. https://doi.org/10.
2174/138920008786927785.
25 Makino, T. (2011). Introduction of “clinical
pharmacognosy”--integration between pharmacognosy
and clinical pharmacy. Yakugaku zasshi: Journal of the
Pharmaceutical Society of Japan 131 (3): 375–82.
https://doi.org/10.1248/YAKUSHI.131.375.
26 Frankel, E.H. (2003). Drug interactions: Basic concepts.
In: Handbook of Food-Drug Interactions, 25–32. Boca
Raton, FL: CRC Press. https://doi.org/10.1201/97802034
90242-7.
27 Gurley, B.J. and Hagan, D.W. (2003). Herbal and dietary
supplement interactions with drugs. Hand book of
food-drug Interactions, (eds. B.J. McCabe, E.H. Frankel,
and J.J. Wolfe), 259–293. Boca Raton: CRC Press.
https://doi.org/10.1201/9780203490242-17.
28 Leclercq, I., Desager, J.P., and Horsmans, Y. (1998).
Inhibition of chlorzoxazone metabolism, a clinical
References 439
probe for CYP2E1, by a single ingestion of watercress.
Clinical Pharmacology & Therapeutics 64 (2): 144–9.
https://doi.org/10.1016/S0009-9236(98)90147-3.
29 Hodek, P., Trefil, P., and Stiborová, M. (2002).
Flavonoids-potent and versatile biologically active
compounds interacting with cytochromes P450.
Chemico-Biological Interactions 139 (1): 1–21. https://
doi.org/10.1016/S0009-2797(01)00285-X.
30 Schulz, V. (2001). Incidence and clinical relevance of the
interactions and side effects of Hypericum preparations.
Phytomedicine: International Journal of Phytotherapy
and Phytopharmacology 8 (2): 152–60. https://pubmed.
ncbi.nlm.nih.gov/11315759/.
31 Fugh-Berman, A. (2000). Herb-drug interactions. The
Lancet 355 (9198): 134–8. https://doi.org/10.1016/
S0140-6736(99)06457-0.
32 Izzo, A.A. and Ernst, E. (2001). Interactions between
herbal medicines and prescribed drugs: a systematic
review. Drugs 61: 2163–75. https://doi.org/10.2165/
00003495-200161150-00002/METRICS.
33 Sugimoto, K.I., Ohmori, M., Tsuruoka, S. et al. (2001).
Different effects of St John’s wort on the
pharmacokinetics of simvastatin and pravastatin.
Clinical Pharmacology & Therapeutics 70 (6): 518–24.
https://doi.org/10.1016/S0009-9236(01)64092-X.
34 Wang, Z., Gorski, J.C., Hamman, M.A. et al. (2001). The
effects of St John’s wort (Hypericum perforatum) on
human cytochrome P450 activity. Clinical Pharmacology
& Therapeutics 70 (4): 317–26.https://doi.org/10.1016/
S0009-9236(01)00127-8.
35 Dürr, D., Stieger, B., KullakUblick, G.A. et al. (2000). St
John’s Wort induces intestinal Pglycoprotein/MDR1
and intestinal and hepatic CYP3A4. Clinical
Pharmacology & Therapeutics 68 (6): 598–604. https://
doi.org/10.1067/MCP.2000.112240.
36 Gurley, B.J., Gardner, S.F., Hubbard, M.A. et al. (2002).
Cytochrome P450 phenotypic ratios for predicting
herbdrug interactions in humans. Clinical
Pharmacology & Therapeutics 72 (3): 276–87. https://
doi.org/10.1067/MCP.2002.126913.
37 Johne, A., Brockmöller, J., Bauer, S. et al. (1999).
Pharmacokinetic interaction of digoxin with an herbal
extract from St John’s wort (Hypericum perforatum).
Clinical Pharmacology & Therapeutics 66 (4): 338–45.
https://doi.org/10.1053/CP.1999.V66.A101944.
38 Beckman, S.E., Sommi, R.W. and, Switzer, J. (2000).
Consumer use of St. John’s wort: a survey on effectiveness,
safety, and tolerability. Pharmacotherapy: The Journal of
Human Pharmacology and Drug Therapy 20 (5): 568–74.
https://doi.org/10.1592/PHCO.20.6.568.35152.
39 Denke, A., Schempp, H., Weiser, D. et al. Biochemical
activities of extracts from Hypericum perforatum L.
Arzneimittelforschung 50 (05): 415–9. https://doi.
org/10.1055/S-0031-1300225/BIB.
40 Gobbi, M., Moia, M., Pirona, L. et al. (2001). In vitro
binding studies with two Hypericum perforatum extractshyperforin, hypericin and biapigenin-on 5-HT6, 5-HT7,
GABAA/benzodiazepine, sigma, NPY-Y1/Y2 receptors and
dopamine transporters. Pharmacopsychiatry 34 (1): 45–8.
https://doi.org/10.1055/S-2001-15458/ID/18/BIB.
41 Stevinson, C., Pittler, M.H., and Ernst, E. (2000). Garlic
for treating hypercholesterolemia: A meta-analysis of
randomized clinical trials. Annals of internal medicine
133 (6): 420–9. https://doi.org/10.7326/0003-4819-1336-200009190-00009.
42 Berthold, H.K., Sudhop, T., and von Bergmann, K.
(1998). Effect of a garlic oil preparation on serum
lipoproteins and cholesterol metabolism: a randomized
controlled trial. Jama 279 (23): 1900–2. https://doi.org/
10.1001/JAMA.279.23.1900.
43 Siess, M.H., Le Bon, A.M., Canivenc-Lavier, M.C. et al.
(1997). Modification of hepatic drug-metabolizing
enzymes in rats treated with alkyl sulfides. Cancer
Letters 120 (2): 195–201. https://doi.org/10.1016/S03043835(97)00309-1.
44 Gallicano, K., Foster, B., and Choudhri, S. (2003). Effect
of shortterm administration of garlic supplements on
singledose ritonavir pharmacokinetics in healthy
volunteers. British Journal of Clinical Pharmacology
55 (2): 199–202. https://doi.org/10.1046/J.1365-2125.
2003.01736.X.
45 Briggs, W.H., Xiao, H., Parkin, K.L. et al. (2000).
Differential inhibition of human platelet aggregation by
selected Allium thiosulfinates. Journal of Agricultural
and Food Chemistry 48 (11): 5731–35.https://doi.org/10.
1021/JF0004412.
46 Duche, J.C., Barre, J., Guinot, P. et al. (1989). Effect of
Ginkgo biloba extract on microsomal enzyme induction.
International Journal of Clinical Pharmacology Research
9 (3): 165–8. https://europepmc.org/article/
MED/2744909.
47 Li, C.L. and Wong, Y.Y. (1997). The bioavailability of
ginkgolides in Ginkgo biloba extracts. Planta Medica
63 (06): 563–5.https://doi.org/10.1055/S-2006957768/BIB.
48 Kressmann, S., Müller, W.E., and Blume, H.H. (2002).
Pharmaceutical quality of different Ginkgo biloba
brands. Journal of Pharmacy and Pharmacology 54 (5):
661–9. https://doi.org/10.1211/0022357021778970.
49 Zhu, M., Chan, K.W., Ng, L.S. et al. (1999). Possible
influences of ginseng on the pharmacokinetics and
pharmacodynamics of warfarin in rats. Journal of
Pharmacy and Pharmacology 51 (2): 175–80. https://
doi.org/10.1211/0022357991772105.
440 21 Clinical Pharmacognosy
50 Bae, E.A., Han, M.J., Choo, M.K. et al. (2002).
Metabolism of 20 (S)-and 20 (R)-ginsenoside Rg3 by
human intestinal bacteria and its relation to in vitro
biological activities. Biological and Pharmaceutical
Bulletin 25 (1): 58–63. https://doi.org/10.1248/BPB.25.58.
51 BeckmannKnopp, S., Rietbrock, S., Weyhenmeyer, R.
et al. (2000). Inhibitory effects of silibinin on
cytochrome P450 enzymes in human liver microsomes.
Pharmacology & Toxicology 86 (6): 250–6. https://doi.org
/10.1111/J.0901-9928.2000.860602.X.
52 Weyhenmeyer, R., Mascher, H. and Birkmayer, J. (1992).
Study on dose-linearity of the pharmacokinetics of
silibinin diastereomers using a new stereospecific assay.
International Journal of Clinical Pharmacology, Therapy,
and Toxicology 30 (4): 134–8. https://pubmed.ncbi.nlm.
nih.gov/1572758/.
53 Liu, Y. and Yang, L. (2006). Early metabolism evaluation
making traditional Chinese medicine effective and safe
therapeutics. Journal of Zhejiang University SCIENCE B
7 (2): 99–106. https://doi.org/10.1631/JZUS.2006.B0099.
54 Zhao, J. and Agarwal, R. (1999). Tissue distribution of
silibinin, the major active constituent of silymarin, in
mice and its association with enhancement of phase II
enzymes: Implications in cancer chemoprevention.
Carcinogenesis 20 (11): 2101–8. https://doi.org/10.1093/
CARCIN/20.11.2101.
55 Størmer, F.C., Reistad, R. and Alexander, J. (1993).
Glycyrrhizic acid in liquorice—evaluation of health
hazard. Food and Chemical Toxicology 31 (4): 303–12.
https://doi.org/10.1016/0278-6915(93)90080-I.
56 Bernardi, M., D’Intino, P.E., Trevisani, F. et al. (1994).
Effects of prolonged ingestion of graded doses of licorice
by healthy volunteers. Life Sciences 55 (11): 863–72.
https://doi.org/10.1016/0024-3205(94)90042-6.
57 Gurley, B.J., Gardner, S.F. and Hubbard, M.A. (2000).
Content versus label claims in ephedra-containing
dietary supplements. American Journal of Health-System
Pharmacy 57 (10): 963–9. https://doi.org/10.1093/AJHP/
57.10.963.
58 Gurley, B. (2000). Extract versus herb: Effect of
formulation on the absorption rate of botanical
ephedrine from dietary supplements containing
Ephedra (ma huang). Therapeutic Drug Monitoring 22
(4): 497. https://doi.org/10.1097/00007691-200008000-
00021.
59 Dulloo, A.G., Seydoux, J., Girardier, L. et al. (2000).
Green tea and thermogenesis: interactions between
catechin-polyphenols, caffeine and sympathetic activity.
International Journal of Obesity 24 (2): 252–8. https://
doi.org/10.1038/SJ.IJO.0801101.
60 Samenuk, D., Link, M.S., Homoud, M.K. et al. (2002).
Adverse cardiovascular events temporally associated
with ma huang, an herbal source of ephedrine. InMayo
Clinic Proceedings, 77 (1): 12–6. Netherlands: Elsevier.
https://doi.org/10.4065/77.1.12.
61 Valenta, R., Karaulov, A., Niederberger. V. et al. (2018).
Allergen extracts for in vivo diagnosis and treatment of
allergy: is there a future? The Journal of Allergy and
Clinical Immunology: In Practice 6 (6): 1845–55. https://
doi.org/10.1016/J.JAIP.2018.08.032.
62 Ojha, A. and Bhargava, S. (2022). International council
for harmonisation (ICH) guidelines. InRegulatory
Affairs in the Pharmaceutical Industry, 47–74.
Massachusetts Academic Press. https://www.ich.org/
63 Erban, T., Harant, K. and Hubert J. (2017). Detailed
two-dimensional gel proteomic mapping of the feces of
the house dust mite Dermatophagoides pteronyssinus
and comparison with D. farinae: Reduced trypsin
protease content in D. pteronyssinus and different
isoforms. Journal of Proteomics 162: 11–9. https://doi.org/
10.1016/J.JPROT.2017.04.021.
64 Spiric, J., Engin, A.M., Karas, M. et al. (2015). Quality
control of biomedicinal allergen products–highly
complex isoallergen composition challenges standard
MS database search and requires manual data analyses.
PloS One 10 (11): e0142404. https://doi.org/10.1371/
JOURNAL.PONE.0142404
65 Chakrabarty, S., Ekramoddoullah, A.K., Kisil. F.T. et al.
(1980). Allergens of Kentucky Blue Grass Pollen: II.
Isolation of Hapten-Like Components from Kentucky
Blue Grass Pollen by Preparative Isoelectrofocussing.
International Archives of Allergy and Immunology
63 (4): 369–82.
66 Spiric, J., Reuter, A. and Rabin, R.L. (2017). Mass
spectrometry to complement standardization of house
dust mite and other complex allergenic extracts. Clinical
& Experimental Allergy 47 (5): 604–17. https://doi.org/
10.1111/CEA.12931
67 Casset, A., Valenta, R. and Vrtala, S. (2013). Allergen
content and in vivo allergenic activity of house dust
mite extracts. International Archives of Allergy and
Immunology 161 (3): 287–8. https://doi.org/10.1159/
000347047
68 Kaul, S., Lüttkopf, D., Kastner, B. et al. (2007). Mediator
release assays based on human or murine
immunoglobulin E in allergen standardization. Clinical
& Experimental Allergy 37 (1): 141–50. https://doi.org/10.
1111/J.1365-2222.2006.02618.X
69 Valenta, R., Twardosz, A., Vrtala, S. et al. (1999). Large
scale production and quality criteria of recombinant
allergens. Arbeiten Aus Dem Paul-Ehrlich-Institut
(Bundesamt fur Sera und Impfstoffe) zu Frankfurt aM
(93): 211–4. https://europepmc.org/article/MED/
11487878.